معرفی
Professor Ute Krengel is a distinguished structural biologist at the University of Oslo, where she has held a full professorship since 2006. She leads research in the Section for Chemical Life Sciences, focusing on proteins of medical interest, particularly enzymes and protein-carbohydrate interactions. Her work combines X-ray crystallography with complementary structural biology techniques to gain atomic-level insights into biological mechanisms with potential therapeutic applications.
Professor Krengel received her PhD from the University of Heidelberg in 1991 with research on the structure and molecular mechanism of p21 ras. Her academic journey includes research positions in Toronto (1991-1993), Groningen (1994-1997), and Gothenburg (1997-2004) before settling at the University of Oslo. In 2018, she served as a visiting professor at ETH Zurich.
Her research program centers on understanding the molecular basis of disease mechanisms, particularly in infectious diseases and cancer, with emphasis on receptor interactions and enzymatic processes. Krengel's laboratory investigates metabolic enzymes, lectins, adhesins, toxins, and anti-cancer antibodies, recognizing that protein-carbohydrate interactions are fundamental to numerous biological processes including metabolism, cellular signaling, differentiation, cell-cell interactions, and immune responses. Her work has significant implications for developing new treatments against human diseases.
Professor Krengel's recent publication record demonstrates consistent productivity and evolving research directions. Her work spans structural characterization of bacterial toxins, anti-tumor antibodies, and enzyme mechanisms, with increasing focus on applications in immunotherapy and infectious disease treatment. The interdisciplinary nature of her research is evident in collaborations across biochemistry, molecular modeling, bioinformatics, NMR spectroscopy, cryo-EM, and mass spectrometry.
Professor Krengel currently serves in significant leadership roles including coordinator of the Norwegian Block Allocation Groups for Synchrotron Research and as the Norwegian representative of the International Glycoconjugate Organization, highlighting her standing in the international scientific community.
Her research is conducted through active collaboration with diverse research groups, ensuring structural characterization is integrated with protein engineering, carbohydrate binding studies, molecular simulations, and drug design. She leads projects on lectins, bacterial toxins, anti-tumor antibodies, and chorismate mutase, contributing to the Bio3 - Chemical Life Sciences research group and participating in the Glyconor Consortium and PX-Oslo structural biology initiatives.
